Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.

Liposils, synthesized via the liposome templating method, offer a promising strategy for enhancing liposome stability by employing a silica coating. This study focuses on the development of nanocarriers utilizing silica-coated nanoliposomes for encapsulating the poorly water-soluble drug, ibrutinib....

Full description

Saved in:
Bibliographic Details
Main Authors: Fareeaa Ashar, Asif Ansari Shaik Mohammed, S Selvamuthukumar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0310492
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846126101214003200
author Fareeaa Ashar
Asif Ansari Shaik Mohammed
S Selvamuthukumar
author_facet Fareeaa Ashar
Asif Ansari Shaik Mohammed
S Selvamuthukumar
author_sort Fareeaa Ashar
collection DOAJ
description Liposils, synthesized via the liposome templating method, offer a promising strategy for enhancing liposome stability by employing a silica coating. This study focuses on the development of nanocarriers utilizing silica-coated nanoliposomes for encapsulating the poorly water-soluble drug, ibrutinib. Ibrutinib-loaded nanoliposomes were meticulously formulated using the reverse-phase evaporation technique, serving as templates for silica coating, resulting in spherical liposils with an average size of approximately 240 nanometers. Comprehensive characterization of the liposil's physical and chemical properties was conducted using various analytical methods, including dynamic light scattering, transmission electron microscopy, Fourier-transform infrared spectroscopy, and X-ray diffraction analysis. Liposils demonstrated superior performance compared to ibrutinib-loaded nanoliposomes, showing sustained drug release profiles in simulated intestinal fluids and resistance to simulated gastric fluid, as confirmed by dissolution studies. Moreover, ibrutinib liposils exhibited a significant increase in half-life (4.08-fold) and notable improvement in bioavailability (3.12-fold) compared to ibrutinib suspensions, as determined by pharmacokinetic studies in rats. These findings underscore the potential of liposils as nanocarriers for orally delivering poorly water-soluble drugs, offering enhanced stability and controlled release profiles, thereby improving bioavailability prospects and therapeutic efficacy. This approach holds promise for addressing challenges associated with the oral administration of drugs with limited solubility, thereby advancing drug delivery technologies and clinical outcomes in pharmaceutical research and development.
format Article
id doaj-art-dcf6f32b9f0a420fbcf25c291f3268f8
institution Kabale University
issn 1932-6203
language English
publishDate 2024-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-dcf6f32b9f0a420fbcf25c291f3268f82024-12-13T05:31:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01199e031049210.1371/journal.pone.0310492Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.Fareeaa AsharAsif Ansari Shaik MohammedS SelvamuthukumarLiposils, synthesized via the liposome templating method, offer a promising strategy for enhancing liposome stability by employing a silica coating. This study focuses on the development of nanocarriers utilizing silica-coated nanoliposomes for encapsulating the poorly water-soluble drug, ibrutinib. Ibrutinib-loaded nanoliposomes were meticulously formulated using the reverse-phase evaporation technique, serving as templates for silica coating, resulting in spherical liposils with an average size of approximately 240 nanometers. Comprehensive characterization of the liposil's physical and chemical properties was conducted using various analytical methods, including dynamic light scattering, transmission electron microscopy, Fourier-transform infrared spectroscopy, and X-ray diffraction analysis. Liposils demonstrated superior performance compared to ibrutinib-loaded nanoliposomes, showing sustained drug release profiles in simulated intestinal fluids and resistance to simulated gastric fluid, as confirmed by dissolution studies. Moreover, ibrutinib liposils exhibited a significant increase in half-life (4.08-fold) and notable improvement in bioavailability (3.12-fold) compared to ibrutinib suspensions, as determined by pharmacokinetic studies in rats. These findings underscore the potential of liposils as nanocarriers for orally delivering poorly water-soluble drugs, offering enhanced stability and controlled release profiles, thereby improving bioavailability prospects and therapeutic efficacy. This approach holds promise for addressing challenges associated with the oral administration of drugs with limited solubility, thereby advancing drug delivery technologies and clinical outcomes in pharmaceutical research and development.https://doi.org/10.1371/journal.pone.0310492
spellingShingle Fareeaa Ashar
Asif Ansari Shaik Mohammed
S Selvamuthukumar
Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.
PLoS ONE
title Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.
title_full Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.
title_fullStr Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.
title_full_unstemmed Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.
title_short Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system.
title_sort enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system
url https://doi.org/10.1371/journal.pone.0310492
work_keys_str_mv AT fareeaaashar enhancementoforalbioavailabilityofibrutinibusingaliposilnanohybriddeliverysystem
AT asifansarishaikmohammed enhancementoforalbioavailabilityofibrutinibusingaliposilnanohybriddeliverysystem
AT sselvamuthukumar enhancementoforalbioavailabilityofibrutinibusingaliposilnanohybriddeliverysystem